FDA warns of dosing errors in compounded versions of Novo's weight-loss drug

From Investing.com: 2024-07-26 18:30:36

The FDA has issued a warning about dosing errors with compounded versions of Novo Nordisk’s weight-loss and diabetes drugs. Some patients have been hospitalized due to overdoses. Compounded drugs may contain additional ingredients, increasing the risk of medication errors. Overdosing on these drugs can lead to severe nausea, vomiting, and low blood sugar levels.

The demand for cheaper versions of these drugs has led to a shortage and a surge in the global market for counterfeit medications. The FDA is concerned about the availability of fake versions of Novo’s diabetes drug Ozempic, Wegovy, and other weight-loss drugs. Compounded drugs pose a higher risk to patients.

The key ingredient in Wegovy and Ozempic, semaglutide, belongs to the GLP-1 class of drugs that help control blood sugar levels and promote a feeling of fullness. Wegovy is available in single-dose pre-filled pens for once-weekly dosing, while Ozempic comes in multiple-dose pre-filled pens for single-patient use. Healthcare providers should provide appropriate guidance on measuring doses to prevent overdose.



Read more at Investing.com: US FDA flags dosing risks from compounded versions of Novo’s weight-loss drug By Reuters